Singapore, Aug. 26 -- Australia-based Vaxxas Pty Ltd, the biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured ~$90 million in its latest financing round.

The financing is one of the largest financings for a private biotech company in Australia this year and includes $49.22 million in new Series D equity and $40 million in debt facilities, with additional commitments under discussion as the Company continues to attract investor interest.

The equity financing was led by SPRIM Global Investments, the venture arm of global life sciences firm SPRIM, with strong participation from new investor LGT Crestone as well as existing investors OneVentures and Brandon Capital-Hostpl...